Childhood lead screening outreach: Medicaid blood lead tests at 12 and 24 months, CDC reference value, the inactive USPSTF topic and plain reminders

A blood lead test for a young child is a small finger prick or blood draw at a well visit, and the marketing around it is easy to get wrong. A page can frighten parents about their home, claim that a test proves a child is safe, offer a home kit as if it replaced the visit, or quote a federal recommendation that no longer exists. A reminder can tell a neighbor or a landlord more than a family wanted to share. This guide covers how a pediatric or family medicine practice, a community or school-based health center, a mobile clinic or a Vaccines for Children provider can invite families to lead screening on the Medicaid requirement, the CDC guidance and the Bright Futures schedule as written, keep the recommendation and the coverage apart, and write calm, accurate pages and messages.

Nine related topics have their own guides and are not repeated here. The practices that test are covered in our guides to pediatric practice marketing, community health center marketing, school-based health center marketing, mobile health clinic marketing and Vaccines for Children provider marketing. Medicaid families are covered in our guide to marketing to Medicaid patients, prenatal care in our guide to OB-GYN practice marketing, consumer test sales in our guide to direct-to-consumer lab testing marketing, and screening days in our guide to health fair and screening event marketing.

What the federal sources say

Medicaid sets the testing requirement for enrolled children, CDC publishes the clinical and public health guidance and the blood lead reference value, HRSA supports the Bright Futures schedule for well visits, and the USPSTF has stepped back from the topic. The points that shape lead screening outreach:

• The Medicaid.gov page Lead Screening (read through an archived copy of August 2026) says all children enrolled in Medicaid, whether coverage is funded through title XIX or XXI, are required to receive blood lead screening tests at 12 months and 24 months, and that a child between 24 and 72 months with no record of a previous blood lead screening test must receive one. It says a risk assessment questionnaire does not meet the requirement; only the blood tests do. It also says CMS has allowed states, since 2012, to request approval for a targeted lead screening program.
• The Medicaid statute, 42 U.S.C. 1396d(r)(1)(B)(iv), lists laboratory tests, including lead blood level assessment appropriate for age and risk factors, among the screening services of the early and periodic screening, diagnostic, and treatment benefit.
• The CDC page About Childhood Lead Poisoning Prevention (updated August 21, 2025, read through an archived copy) says there are no safe levels of lead in the blood, that no safe blood lead level in children has been identified, and that CDC uses a blood lead reference value of 3.5 micrograms per deciliter. It lists sources of exposure that include chipping or peeling paint in homes or buildings built before 1978, water from lead pipes, soil near airports, highways or factories, some imported candies, traditional medicines, toys and jewelry, and certain jobs and hobbies.
• The CDC page Testing for Lead Poisoning in Children (updated March 11, 2026, read through an archived copy) says a blood lead test is the best way to find out if a child has lead poisoning, that a child with lead poisoning may not have visible signs or symptoms, and that parents can talk to their child’s healthcare provider about a test. It says children at risk should be tested, including children who live or spend time in a building built before 1978, who are immigrants, refugees or recently adopted from less developed countries, or who live or spend time with someone whose work or hobbies expose them to lead.
• The CDC page CDC Updates Blood Lead Reference Value (reviewed August 25, 2026, read through an archived copy) says CDC lowered the reference value from 5.0 to 3.5 micrograms per deciliter on October 28, 2021, that the value is based on the 97.5th percentile of blood lead levels in U.S. children aged 1 to 5, and that it identifies children with higher levels than other children, so that action can be taken sooner. A reference value is a public health trigger, not a safe level.
• The CDC page Recommended Actions Based on Blood Lead Level (updated August 21, 2025, read through an archived copy) says a finger-prick or heel-prick result at or above the reference value should be confirmed with a venous sample. For children not enrolled in Medicaid, it says to focus screening on high-risk neighborhoods and children using local data, and, in the absence of such plans, recommends universal blood lead testing.
• The USPSTF page Elevated Blood Lead Levels in Children and Pregnant Women: Screening, checked October 30, 2026, is marked inactive. It says the USPSTF recognizes the importance of screening and testing, does not wish to duplicate the work of others, will not update its 2019 recommendation, and points readers to the CDC recommendations instead.
• The HRSA page Bright Futures (date last reviewed March 2024, read through an archived copy) says HRSA funds the Bright Futures guidelines for preventive care from birth to age 21 through a cooperative agreement with the American Academy of Pediatrics, and that the HRSA Administrator accepts updates to the periodicity schedule. The Bright Futures periodicity schedule (updated February 2025) lists lead risk assessment at well visits in infancy and early childhood, and a blood test or risk assessment at 12 and 24 months, based on universal screening requirements for patients with Medicaid or in high prevalence areas.

The USPSTF change is the one that catches practice pages out. Its 2019 statement, as an archived copy from December 2023 shows, found the evidence insufficient to assess screening of children 5 or younger without symptoms (an I statement), and a page written before the topic went inactive may still quote it, or may claim the opposite, that the USPSTF recommends screening for every child. On October 30, 2026, the USPSTF page said the 2019 recommendation will not be updated and sent readers to CDC. A practice page should cite the Medicaid requirement, CDC guidance and the Bright Futures schedule, and leave the USPSTF out of the claim, or mention only that it defers to CDC.

The Task Force itself has changed. In Kennedy v. Braidwood Management, decided June 27, 2025, the Supreme Court held that Task Force members are inferior officers whose appointment by the Secretary of HHS is consistent with the Appointments Clause. On September 17, 2026, HHS announced eight new members who join the eight already serving. Neither event revived the lead topic as of October 30, 2026. The CDC pages cited here were read through archived copies, since the CDC site did not answer our direct requests, and we could not confirm developments after that date. A practice page should quote the guidance in force on the day it is written and record that date in its review notes.

Two points shape the marketing. First, the requirement and the guidance differ by payer: Medicaid requires blood tests at 12 and 24 months and a catch-up test up to 72 months, while CDC guidance for other children depends on local risk and local plans, with universal testing where no plan exists. A page that says “the law requires every child to be tested” overstates the source. Second, a test result is a number that leads to a conversation, follow-up testing and, where needed, a health department visit; it is not a verdict on a family’s home or care.

Lead screening pages and claims that need rewriting

Google’s search suggestions, which we checked on October 30, 2026, offer “lead screening for kids”, “lead screening for babies”, “lead screening for toddlers”, “lead screening for 1 year old” and “lead screening for 2 year old” to a person who types “lead screening for”, and “lead screening near me”, “lead testing near me for kids” and “how is lead screening performed” to a person who types “lead screening near”. For “blood lead test” they offer “blood lead test for child”, “blood lead test results”, “blood lead test cost” and “blood lead test meaning”, and for “lead testing for kids” they offer “lead test for kids in spanish” and “lead test for kids at home”. Suggestions with code terms belong to the billing staff, not the parent page. The pattern is clear: parents want to know when the test happens, how it is done, what it costs, what a result means, and whether they can do it at home.

A page that holds up says which ages the practice tests and why, names the Medicaid requirement and CDC guidance with their dates, explains how the sample is taken in plain words, says what happens after a result at or above the reference value, states coverage with its conditions, and offers the page in Spanish where families speak it.

Phrases that need rewriting:

• “Your home could be poisoning your child. Test now!” A fear claim aimed at parents. Say what CDC lists as sources of exposure, and that a blood test at the ages the practice follows shows whether a child has been exposed.
• “A normal result means your child is safe from lead.” CDC says no safe blood lead level in children has been identified. Say a result below the reference value means no follow-up action is needed now, and that the care team will advise on later tests.
• “The USPSTF recommends lead screening for all children.” The USPSTF topic is inactive and its 2019 statement found the evidence insufficient for children without symptoms. Cite CDC and the Medicaid requirement instead.
• “Federal law requires every child to be tested at 1 and 2.” The requirement applies to children enrolled in Medicaid. For other children, CDC guidance depends on local risk and local plans. State the difference.
• “Our lead test is free.” Medicaid covers the test for enrolled children and private plan coverage depends on the plan. State the conditions, or say the practice checks coverage first.
• “Order a home lead test and skip the doctor.” A result needs confirmation and follow-up from a clinician and, at higher levels, the health department. Say the practice can test at a visit, and what it does with the result.
• “Our treatment removes lead from your child’s body.” A treatment claim with no source. Say the care team follows CDC’s recommended actions for the child’s level, and works with the local health department.
• “We’ve tested thousands of kids and found lead in hundreds of homes.” Numbers with no source, and a hint about other families’ homes. Remove them unless they come from the practice’s own documented and reviewed records, with their date and limits stated.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. Quoting the federal sources as written, with each one named and dated, stays inside that standard; turning a federal statement into a promise to a parent does not.

Symptoms, urgent signs and 911 on every page and in every tool

CDC says a child with lead poisoning may not have visible signs or symptoms, which is the reason for testing at set ages rather than waiting for a sign. A lead page should say so plainly, and should not list symptoms in a way that invites parents to rule lead out by watching their child. The CDC page Lead Exposure Symptoms and Complications (updated August 27, 2026, read through an archived copy) is the source to link for parents who want more.

Put a plain line on the page, on flyers and in reminders: if your child may have swallowed something that contains lead, such as a paint chip, a piece of jewelry or a small toy part, call the practice now; if your child is having trouble breathing, has a seizure or cannot be woken, call 911.

The same wording belongs in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools. A tool should send any message about a child who swallowed something, a seizure or trouble breathing to 911 or the on-call clinician at once and alert staff, pass questions about a result to a clinician, and never tell a parent whether a number is serious or whether a child needs treatment. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages.

Who to invite: infants, toddlers, catch-up tests and families at risk

The ages are clear for Medicaid and set by local plans for everyone else. That makes the invitation simple: it is part of the 1 year and 2 year visits, not a sign that something is wrong with a family’s home.

Keep these points:

• Children enrolled in Medicaid: invite to the 12 month and 24 month well visits, say a blood lead test is part of them, and invite children 24 to 72 months with no test on record to a catch-up test. A questionnaire alone does not meet the Medicaid requirement, so a page should not offer one as a substitute.
• Children not enrolled in Medicaid: follow the practice’s local plan, the state and local health department’s guidance, and the Bright Futures schedule, and say on the page which ages the practice tests and why. Where no local plan exists, CDC recommends universal testing.
• Families new to the country and children recently adopted from abroad: CDC lists immigrant, refugee and recently adopted children among those at risk. Invite them to a test as part of their first visits, in their language, without singling out a country or a group in public ads.
• Families in older homes or with lead-related work or hobbies: CDC lists these as risk factors. A page can say a parent should tell the care team about a home built before 1978, renovation work, or a job or hobby that involves lead, and the team will decide on testing.
• Pregnancy: the USPSTF topic also covered pregnant persons and is inactive. Leave prenatal lead testing to the obstetric clinician and the practice’s own protocol, and do not run a screening campaign on it without clinical review.

Our guides to pediatric practice marketing, marketing to Medicaid patients and community health center marketing cover the wider rules for those pages.

After the test: confirming, follow-up and the health department

CDC’s recommended actions turn on the result. A finger-prick or heel-prick result at or above 3.5 micrograms per deciliter should be confirmed with a venous sample. Below the reference value, CDC recommends education about sources of lead and follow-up testing at intervals based on the child’s age. At or above it, CDC recommends education, reporting to the state or local health department, follow-up testing and, at higher levels, an environmental investigation of the home.

A page should describe this in plain words and in the practice’s own terms: who calls the family with the result, how soon, what a confirmation test involves, and that the health department may contact the family. Do not promise what the health department will do or how fast; that is set state by state and locally. Do not name medicines or treatments on a marketing page; treatment choices belong to the clinician and the family. Do not describe a family’s home as dangerous or unsafe on a public page; that is a judgment for the inspection, if one happens.

Home inspection and repair belong to other professionals. The EPA page Reduce the Risk of Lead Exposure at Home (last updated October 5, 2026) says the federal government banned the sale of lead-based paint for use in homes and childcare facilities in 1978, and points families to lead-safe certified contractors for renovation, repair and painting in older homes; CDC points families who want their home tested to a certified lead inspector. A practice can link those pages. It should not sell or recommend a particular inspector, contractor or product, or accept payment from one.

Coverage: Medicaid, private plans and free test days

Medicaid covers lead testing for enrolled children; CDC’s testing page says the cost of blood lead testing for children enrolled in Medicaid is covered. Private plans follow 42 U.S.C. 300gg-13, which requires group health plans and health insurers to cover, without cost sharing, evidence-informed preventive care and screenings for infants, children and adolescents provided for in the comprehensive guidelines supported by HRSA, as well as USPSTF services rated A or B. The lead topic has no USPSTF A or B rating, so plan coverage turns on the HRSA-supported Bright Futures schedule and on the plan itself. Keep the recommendation and the coverage apart on the page, say the practice checks coverage before the visit, and do not write “free under the ACA”. Cash prices for a test or a visit follow our guides to advertising cash prices and good faith estimates for self-pay patients.

A free lead test day at a community center, a school or a housing site, or a gift for coming in, follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and that the terms of the offer should be stated at the outset. Under 42 U.S.C. 1320a-7a(a)(5), civil penalties can apply to a person who offers or transfers remuneration to a Medicare or state health care program beneficiary that the person knows or should know is likely to influence the beneficiary to order or receive items or services from a particular provider, practitioner or supplier. A gift card for Medicaid families who come in for a test needs counsel’s review before it runs. An event also needs a written plan for who gives families their results, who orders confirmation tests and who reports to the health department. Our guides to health fair and screening event marketing and mobile health clinic marketing cover event rules.

Home kits, supplements and products sold alongside

Parents search for home lead tests, and a practice may be offered kits, filters, cleaning products or supplements to sell next to its testing program. A home kit for paint, dishes or water is not a blood test, and a blood sample a parent collects at home still needs a clinician to read and act on the result. Our guide to direct-to-consumer lab testing marketing covers consumer test claims. The FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed. Name no product, make no claim that a supplement, a filter, a food or a device prevents or treats lead poisoning or removes lead from the body, and follow our guide to selling supplements in a medical practice.

Food is a topic parents ask about. The FDA guidance Action Levels for Lead in Processed Food Intended for Babies and Young Children (January 2025) sets levels for processed food for children under two as part of FDA’s Closer to Zero work. A page can link it. It should not name or rank brands, or tell parents a food is safe or unsafe.

Recall texts, letters and reminders

Lead screening reaches families through recall lists: children due for the 1 year or 2 year visit, children 2 to 6 with no test on record, and children due for a follow-up test. Under 45 CFR 164.501, a communication about the practice’s own treatment for an individual, such as a reminder to come in for a recommended service, can fall outside the definition of marketing, while a message that promotes a third party’s product or service generally needs a signed authorization under 45 CFR 164.508.

The words in the message matter as much as the rule. A text, a postcard or a voicemail can be seen by a relative, a babysitter, a roommate or a landlord. Keep these points:

• Invite to the visit: “[Practice name]: [child’s first name] is due for a well visit. Call [phone] or reply to book.” A routine 1 year or 2 year reminder can mention that a lead test is part of the visit; a follow-up reminder after a result should not.
• Never put a result, a level or the words lead poisoning in a text, a postcard, a voicemail or an email subject line.
• Use the contact method and number the parent or guardian chose, and keep the caller ID and the sender name neutral.
• Send messages to the person who may act for the child; 45 CFR 164.502(g) defers to state and other law on when a parent acts as a minor’s personal representative, and custody arrangements vary.
• Give every message an easy opt-out, and honor it.

Our guides to text message appointment reminders and the patient recall system cover consent, timing and opt-outs.

Families, landlords, schools and who may hear what

Relatives book visits, child care centers ask for records, and a landlord may call after a health department visit. Under 45 CFR 164.510(b), a covered entity may share information relevant to a family member’s or friend’s involvement in a patient’s care when the patient, or the person acting for the child, agrees or does not object, or, when they are not present or cannot agree, when the professional judges it is in the patient’s best interest. The intake team should ask the parent what may be shared and with whom. A landlord, an employer or a child care center is not a family member involved in care, and a request from one goes to the practice’s privacy officer, not to the front desk. Reporting a result to the health department follows the practice’s reporting duties, which are set state by state, and is not a marketing message.

Partners, sponsors and referral payments

Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state.

For a lead screening program, keep these points:

• Do not pay a child care center, school, housing group or community group per child tested or per family referred, and do not accept payment from a lab, an inspector, a contractor or a product maker for the families the practice sends them, without counsel’s review.
• Keep industry funding away from what the program recommends after a result; our guide to Open Payments and the Sunshine Act covers disclosure.
• Point families to the health department and to public lists of certified inspectors and contractors, and tell them they can choose; our guide to patient and physician referrals covers referral rules.

Privacy, pixels and ads

A booking for a follow-up lead test, a result page in the portal or a page about lead in the home can say something sensitive about a child’s health and a family’s housing. Keep form answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place, language settings and search terms such as “lead testing near me for kids”, and should not be built from a list of children with a result, families in a health department referral, or Medicaid enrollees taken from the practice’s records. Ad copy should not address the reader as a parent of a poisoned child, and should not target a neighborhood with wording that singles it out.

Tone, access and family stories

Lead is a hard topic for parents, who may feel blamed for their home or their child’s exposure, and for families who rent and cannot repair what they find. Present testing as routine care at the 1 year and 2 year visits, use calm words, and keep out alarm and blame: no images of peeling paint on a child’s crib, no “is your home poisoning your kids?”, no wording that suggests a parent failed. Write in plain words, offer the page in the languages the practice’s families speak, and link the Spanish versions of federal pages where they exist. The Department of Justice Guidance on Web Accessibility and the ADA describes website features such as text alternatives, enough color contrast and the ability to resize text that help people with disabilities use a site; our guide to Spanish language medical marketing covers translation.

A parent’s story about getting a child tested can help others. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. Use a story only if the parent chose to share it in writing, get a signed authorization under 45 CFR 164.508 where the practice is a covered entity, leave out the child’s result, address and school, say if the family received anything for taking part, let them review the final version, and let them withdraw it later. Do not show the child’s face without separate written consent from the parent. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two lead screening messages

Illustration: a flyer reads “Is your home poisoning your child? The USPSTF says all kids must be tested for lead. Our free test proves your child is safe in 5 minutes, and our treatment removes lead fast. Or order our home kit and skip the visit! We’ve found lead in hundreds of local homes.” It frightens and blames parents, misstates an inactive USPSTF topic and the Medicaid rule, promises safety from a single result, makes a treatment claim, offers a kit as a substitute for clinical follow-up, mixes a free claim with no conditions, and uses numbers with no source.

Illustration: a second flyer for the same practice reads “A blood lead test is part of the 1 year and 2 year checkups at [Practice name]. Medicaid requires the test at 12 and 24 months for enrolled children, and a catch-up test up to age 6 for children never tested. CDC says a child with lead in the blood may show no signs, so testing is the way to know. The test takes a small blood sample; if a result is at or above CDC’s reference value, we confirm it and talk with you about next steps. Medicaid covers the test; other plans vary, and we check your coverage first. If your child swallowed something that may contain lead, call us at [phone]. If your child is having trouble breathing or a seizure, call 911. [days and hours].” It quotes the sources, says what a test is and is not, states the coverage conditions and gives the urgent lines.

Checklist before a lead screening campaign goes live

• Copy built on the Medicaid.gov Lead Screening page and 42 U.S.C. 1396d(r), the CDC testing, reference value and recommended actions pages, and the Bright Futures periodicity schedule, each named and dated; the USPSTF lead topic described as inactive, not as a recommendation; the sources checked again on the day the page is written, with the date recorded.
• The Medicaid requirement kept apart from CDC guidance for other children; no “the law requires every child” claim; no questionnaire offered as a substitute for the Medicaid blood tests.
• No fear or blame wording, no “your child is safe” promise from a result, no treatment claims and no medicine names; a result described as a number that leads to follow-up, with the reference value explained as a trigger, not a safe level.
• The urgent lines on pages, flyers, voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools: call the practice for a swallowed object, 911 for trouble breathing, a seizure or a child who cannot be woken.
• Coverage described as Medicaid and 42 U.S.C. 300gg-13 state it, with plan coverage checked per child; no “free for everyone”; free test days and gifts reviewed under 16 CFR 251.1 and 42 U.S.C. 1320a-7a(a)(5).
• Reminders, postcards, caller ID names, voicemails and subject lines carry no result, no level and no follow-up reason; messages go to the parent or guardian through the contact method they chose.
• Landlord, employer and child care requests sent to the privacy officer; health department reporting handled under the practice’s reporting duties, not marketing.
• No home kit, filter, food, supplement or product claims and no brand names; no payments to or from labs, inspectors, contractors or community partners without counsel’s review; family stories with signed authorizations and no result, address or school.
• Patient lists and results stay out of ad audiences and tracking tools; the page offered in the languages the practice’s families speak and checked against the ADA web guidance.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including pediatric and family medicine practices, community and school-based health centers and mobile clinics. For a lead screening program, that means a site that builds its pages on the Medicaid requirement, the CDC guidance and the Bright Futures schedule as written and dated, keeps the Medicaid rule apart from local guidance and both from coverage, and answers “lead screening for kids” and “lead testing near me for kids” searches calmly and honestly, plus appointment request pages that book the 1 year and 2 year visits and keep results off the web and away from tracking tools. Our front desk tools send any message about a swallowed object, a seizure or trouble breathing to 911 or the on-call clinician and alert staff, hand result questions to a clinician, and do not tell anyone whether a level is serious. We do not decide who should be tested or treated; your clinicians and families do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• Medicaid.gov: Lead Screening (archived copy, August 2026)
• 42 U.S.C. 1396d: Definitions (subsection (r), early and periodic screening, diagnostic, and treatment services)
• CDC: About Childhood Lead Poisoning Prevention (updated August 21, 2025)
• CDC: Testing for Lead Poisoning in Children (updated March 11, 2026)
• CDC: Lead Exposure Symptoms and Complications (updated August 27, 2026)
• CDC: People at Increased Risk for Childhood Lead Poisoning (updated January 31, 2024)
• CDC: Recommended Actions Based on Blood Lead Level (updated August 21, 2025)
• CDC: CDC Updates Blood Lead Reference Value (reviewed August 25, 2026)
• USPSTF: Elevated Blood Lead Levels in Children and Pregnant Women: Screening (inactive, checked October 30, 2026)
• HHS: Secretary Kennedy Announces New Appointments to U.S. Preventive Services Task Force (September 17, 2026)
• Kennedy v. Braidwood Management, Inc. (U.S. Supreme Court, decided June 27, 2025)
• HRSA: Bright Futures (date last reviewed March 2024)
• Bright Futures: Recommendations for Preventive Pediatric Health Care, periodicity schedule (updated February 2025)
• MedlinePlus: Lead Poisoning (last updated August 27, 2026)
• EPA: Reduce the Risk of Lead Exposure at Home (last updated October 5, 2026)
• FDA: Guidance for Industry: Action Levels for Lead in Processed Food Intended for Babies and Young Children (January 2025)
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• 42 U.S.C. 300gg-13: Coverage of preventive health services
• 45 CFR 164.501: Definitions
• 45 CFR 164.502: Uses and disclosures of protected health information: General rules
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 45 CFR 164.510: Uses and disclosures requiring an opportunity for the individual to agree or to object
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7a: Civil monetary penalties
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy
• U.S. Department of Justice: Guidance on Web Accessibility and the ADA

More in Physician specialty marketing